

# Russell Anderson

Partner



randerson@cooley.com

+44 (0) 20 7556 4480

London

Mergers and Acquisitions

Venture Capital

Technology

Life Sciences

Russell counsels companies through a broad range of domestic and cross-border M&A and venture capital transactions with a focus on the tech and life sciences sectors. Russell was previously seconded to a major financial institution where he advised on a number of asset sales and corporate governance issues as part of the EMEA consumer legal team. He is a co-chair of the firm's LGBTQ+ Affinity Group and a member of the firm's pro bono committee.

**His recent experience includes advising:**

- **AAC Clyde Space** on its acquisition of SpaceQuest, a satellite technology developer based in Virginia
- **Adestra**, a provider of email, marketing and transaction automation software, on its sale to Upland for \$56 million
- **Alvotech Holdings**, a global biopharmaceutical company, on its combination with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II, with the combined company valued at \$2.25 billion
- **Bit Bio**, a synthetic biology company, on its \$41 million Series A financing
- **Brandwatch**, a global leader in digital consumer intelligence and social media listening, on its agreement to sell to Cision for \$450 million
- **Brandwatch**, the world's premier social suite, on its acquisition of Paladin, a comprehensive influencer marketing platform
- **Chegg** in connection with its acquisition of Busuu for approximately \$436 million
- **Cision**, a global comprehensive communications platform, on its acquisition of Factmata, an advanced social and news media monitoring company
- **Cisco** on its bolt on acquisition of Ensoft, a specialist in developing network software
- **DocuSign**, on its \$188 million acquisition of Seal Software
- **HitGen**, on its acquisition of research company, Vernalis Research (R&D) Limited, from Ligand Pharmaceuticals
- **Hummingbird Bioscience**, a clinical-stage biotech company, on its US\$19 million Series B financing
- **Luna Innovations**, a developer of fibre-optics based technologies, on its acquisition of OptaSense from QinetiQ
- **Mission Therapeutics**, a drug discovery and development company, on its £12 million Series B financing

- **Redx Pharma**, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a \$425 million and contingent value right transaction.
- **Style Analytics Limited**, a factor and ESG exposure analytics provider, on its sale to Investment Metrics
- **Tusk Therapeutics**, a UK immuno-oncology company, on its sale to Roche for up to \$759 million
- **UiPath** in connection with its acquisition of Re:Infer

#### **Pro bono**

Russell regularly advises not-for profits and charities on corporate governance issues.

## Education

College of Law, Moorgate  
LPC, 2012

University of Leeds  
LLB, 2011

## Admissions & Credentials

England and Wales